3 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 3 | Recruiting 3 |
Follow Phanes Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 350 | 2023-03-15 | 2026-09-28 |
| Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel - Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 40 | 2022-08-11 | 2026-05-19 |
Biliary Tract Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1)
Albumin-Bound Paclitaxel (2) · Gemcitabine (2) · Paclitaxel (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · EC regimen (1) · Folfox protocol (1) · Irinotecan (1) · PM 01183 (1) · Pemetrexed (1) · Pharmaceutical Preparations (1)
United States (3)